Each NeuroPI module is prepared by distinguished faculty who are acknowledged leaders in their respective fields. Each module is composed of a set of multiple-choice items with preferred responses, instructions on how to collect cases to assess one's practice, and resources for creating and implementing an improvement program. Participants are able to compare their performance pre- and post-intervention to assess what changes have occurred in their practice.
As a result of this program the learner will:
As a result of this program, the participant will determine individual practice gaps and address them through a performance improvement plan designed to improve competence, performance, and patient outcomes.
July 12, 2012
This module is eligible for CME credits for three years from the release date.
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved.
The American Academy of Neurology (AAN) is not requesting any individually identifiable health information as defined by HIPAA privacy guidelines. The data you submit to the AAN through NeuroPI is de-identified, as it neither identifies nor provides a reasonable basis to identify an individual. All information submitted to the AAN through NeuroPI is confidential. Data may be used and presented anonymously and in aggregate by the AAN.
Patients must be tracked separately from NeuroPI to ensure confidentiality. Within the NeuroPI modules, your patients will be identified using a 4-digit patient code that you create. Any other indentifying information is strictly prohibited. Please use the NeuroPI Patient Tracker to create your 4-digit patient codes for your personal reference. The NeuroPI Patient Tracker should not be shared with AAN.
DAVID KNOPMAN, MD, FAAN
Professor of Neurology
Mayo Clinic, Rochester, MN
*Dr. Knopman has received personal compensation for activities with Lilly Pharmaceuticals as a data safety monitoring board member. Dr. Knopman has received personal compensation in an editorial capacity for Neurology.
GREGORY JICHA, MD
Associate Professor of Neurology
University of Kentucky College of Medicine, Lexington, KY
*Dr. Jicha has received personal compensation for activities with Lilly Pharmaceuticals as a scientific advisory board member. Dr. Jicha has received contract research support from Jannsen, Baxter and Medivation.
BRIAN OTT, MD, FAAN
Professor of Neurology Alpert Medical School of Brown University, Providence, RI
*Dr. Ott has received research grant support rom Univita, Pfizer/Jannsen, Baxter, and Ely Lilly/Avid.
DONALD J. IVERSON, MD, FAAN
Humboldt Neurological Medical Group, Eureka, California
*Dr. Iverson has nothing to disclose.
RALPH F. JOZEFOWICZ, MD, FAAN
AAN Board Member
University of Rochester, Rochester, New York
*Dr. Jozefowicz has received personal compensation in an editorial capacity for The Neurologist.
CYNTHIA L. COMELLA, MD, FAAN
Education Committee Chair
Rush University Medical Center, Chicago, Illinois
*Dr. Comella has received personal compensation for activities with Ipsen, Merz Pharma, Allergan, Inc., UCB Pharma, and Eisai Inc., as a consultant. Dr. Comella's institution has received research support from Merz Pharma, Allergan, Inc., Ipsen, and Boehringer Ingelheim Pharmaceuticals, Inc.
JONATHAN P. HOSEY, MD, FAAN
Practice Committee Chair
Geisinger Medical Center, Danville, Pennsylvania
*Dr. Hosey has nothing to disclose.
Tracy King, MA, Senior Manager, Education
*Ms. King has nothing to disclose.
Lucy Persaud Samaroo, Program Manager, Education
*Ms. Persaud Samaroo has nothing to disclose.
Rebecca J. Swain-Eng, MS, Senior Manager, Measurement and Implementation
*Ms. Swain-Eng has nothing to disclose.
Susan Rodmyre, Director, Education
*Ms. Rodmyre has nothing to disclose.
Lori Strachota, Program Manager, Conference Management, Registration
*Ms. Strachota has nothing to disclose.
+ Unlabeled Use of Products/Investigational Use Disclosure